


3Q FY2025

FINANCIAL RESULTS OVERVIEW





Thank You for Your Attention

Safe Harbor

This presentation contains forward-looking statements (including, without limitation, information, and future guidance on the company's revenue, revenue growth, earnings per share, operating cash flow, capital expenditures, net interest and other/expense, impact of acquisitions and related financing, share repurchases, dividends, diluted share counts, and currency exchange rates) that involve risks and uncertainties that could cause results of Agilent to differ materially from management's current expectations. The words "anticipate," "plan," "estimate," "expect," "intend," "will," "should," "forecast," "project" and similar expressions, as they relate to the company, are intended to identify forward-looking statements.

In addition, other risks that the company faces in running its operations include the ability to execute successfully through business cycles; the ability to

successfully adapt its cost structures to continuing changes in business conditions; ongoing competitive, pricing and gross margin pressures; the risk that our strategic and cost-cutting initiatives will impair our ability to develop products and remain competitive and to operate effectively; the impact of geopolitical uncertainties on our markets and our ability to conduct business; the impact of currency exchange rates on our financial results; the impact relating to or arising from changes to tariffs, import/export or trade policies; the ability to improve asset performance to adapt to changes in demand; the ability to successfully introduce new products at the right time, price and mix, and other risks detailed in the company's filings with the Securities and Exchange Commission, including our quarterly report on Form 10-Q for the quarter ended April 30, 2025.


The company assumes no obligation to update the information in these presentations. These presentations and the Q&A that follows include non-GAAP measures. Non-GAAP measures exclude charges primarily related to restructuring and other related costs, asset impairments, amortization of intangibles, transformational initiatives, acquisition and integration costs, and net (gain) loss on equity securities. We also exclude any tax benefits that are not directly related to ongoing operations and which are either isolated or are not expected to occur again with any regularity or predictability. With respect to the company's guidance, most of these excluded amounts pertain to events that have not yet occurred and are not currently possible to estimate with a reasonable degree of accuracy. Accordingly, no reconciliation to GAAP amounts has been provided.

Agilent 3Q25 Results

Revenue Beat, EPS at High End; FY25 Core Growth⁽¹⁾ Outlook Increased



- Revenue \$1.74B, exceeded top of guidance by more than \$60M despite dynamic market conditions
- EPS \$1.37⁽²⁾, +4% YoY, at the high end of guidance
- Operating margin 25.1%⁽²⁾, stable versus H1'25 in challenging environment
- Raised FY25 core growth⁽¹⁾ outlook to 4.5% and revenue increased \$150M at the midpoint of guidance



Revenue

\$1.74B

+10.1% reported

+6.1% core⁽¹⁾⁽²⁾

+2.1% FX, +1.9% M&A



Operating Margin

25.1%⁽²⁾

-230 bps y/y



EPS

\$1.37⁽²⁾

+4% y/y



Capital Allocation

\$362M operating cash flow

\$85M to purchase 0.7M shares

\$103M invested in capex

\$71M in dividends


(1) Core growth is reported growth adjusted for the effects of acquisitions and divestitures, and FX.

(2) Presented on a non-GAAP basis; reconciliations to closest GAAP equivalent provided on Agilent's Investor Relations website.

Growth Momentum

five consecutive quarters of accelerating core growth⁽¹⁾

\$1.74B Q3 Reported Revenue	+10.1% Q3 Reported Growth	+6.1% ⁽¹⁾⁽²⁾ Q3 Core Growth
---------------------------------------	-------------------------------------	--



* - 2Yr Core Growth Stack Sequential Increase

FY25 Outlook

4.5% ↑

Core Growth⁽¹⁾ at midpoint of range

Up +150 bps vs prior guidance

4Q25 Outlook

5.4% ↑

Core Growth⁽¹⁾ at midpoint of range

Q4 sustaining 2Yr core growth stack uptrend

Innovation and funnel strength building a durable foundation for growth


(1) Core growth is reported growth adjusted for the effects of acquisitions and divestitures, and FX.
 (2) Presented on a non-GAAP basis; reconciliations to closest GAAP equivalent provided on Agilent's Investor Relations website.

All Segments Delivered Growth in Q3 Led by LDG

All three segments exceeded expectations; innovation in LC & LC/MS and GC platforms highlight growth momentum

- (1) Core growth is reported growth adjusted for the effects of acquisitions and divestitures, and FX.
(2) Presented on a non-GAAP basis; reconciliations to closest GAAP equivalent provided on Agilent's Investor Relations website.

LDG 17.6% Operating Margin ⁽²⁾	+7% Core Growth ⁽¹⁾⁽²⁾ +14% Reported	<ul style="list-style-type: none">• LC & LC/MS strong• CDMO (siRNA, GLP-1) drives growth
ACG 33.3% Operating Margin ⁽²⁾	+5% Core Growth ⁽¹⁾⁽²⁾ +8% Reported	<ul style="list-style-type: none">• Services & Consumables solid• China tariff pull-forward impact absorbed
AMG 21.8% Operating Margin ⁽²⁾	+5% Core Growth ⁽¹⁾⁽²⁾ +7% Reported	<ul style="list-style-type: none">• GC & GC/MS strength• Chemicals & Semicon capex investment




GEOGRAPHY

PRODUCT TYPE

Broad-Based Growth Across All Major Regions

- Americas
39% of Agilent Revenue⁽²⁾
- Europe
28% of Agilent Revenue⁽²⁾
- Asia-Pacific
33% of Agilent Revenue⁽²⁾



(1) Core growth is reported growth adjusted for the effects of acquisitions and divestitures and FX; reconciliations to closest GAAP equivalent provided on Agilent's Investor Relations website.
(2) % of Q3'25 Agilent revenue.



GEOGRAPHY


PRODUCT TYPE

Q3 revenue mix

Consumables, services, & informatics up 100 bps year-over-year

- Consumables
Services
Informatics
- Instruments

% of total revenue



Q3 REVENUE Broad-Based End-Market Growth, Led by Pharma and CAM

Broad-based end market growth, led by Pharma and Chemicals & Advanced Materials

		Q3 Core Growth ⁽¹⁾ Results	Share of Agilent Revenue ⁽²⁾
Pharma	Excellent growth the result of strong portfolio and team on improving capital spending environment	+9%	36%
Academia & Government	China and resilient services and consumables offsets expected weak instrument spending in the US.	+1%	8%
Diagnostics & Clinical	Dako cancer diagnostics business delivers high-single digit growth ex-China	+4%	15%
Chemicals & Advanced Materials	Increasing Chemical market capital investment, cont'd Advanced Materials strength on semi fab build-outs	+10%	23%
Food	Food safety regulations driving strong growth in Europe and Asia ex-China	+7%	9%
Environmental & Forensics	Reduced public spending in the US & China leads to decline, while PFAS remains very strong ex-US	-5%	9%

(1) Core growth is reported growth adjusted for the effects of acquisitions and divestitures and FX; reconciliations to closest GAAP equivalent provided on Agilent's Investor Relations website.

(2) % of Q3'25 Agilent revenue.

IGNITE Innovation Pipeline Driving Growth

Delivering workflow
excellence and
productivity gains



01

Infinity III LC

Next Gen HPLC

strong adoption, mid-teens
growth, customers coming
back for repeat orders

Ease-of-use and
increased lab
productivity



02

Pro IQ LC/MS

Single-quad LC/MS

ahead of launch forecast,
funnel expanding in pharma

Unprecedented range
expands application
possibilities



03


Dako Omnis Family

Automated IHC & ISH Cancer Dx

enables fully-automated
sample processing for
pathology labs of all sizes

Reduced handling
increases efficiency


Raised FY25 Revenue Guidance on Strong Q3 Momentum⁽¹⁾



(1) As of August 27, 2025, based on forecasted currency exchange rates. Presented on a non-GAAP basis.
 (2) Core growth is reported growth adjusted for the effects of acquisitions and divestitures, and FX.
 (3) The 2024 Stock Repurchase Program that authorized up to \$2 billion was approved by the Board in May 2024. The new program became effective on August 1, 2024 and will commence upon the termination of our 2023 Stock Repurchase Program.

Q425 guidance⁽¹⁾

Volume driving margin expansion



\$9M
Q4

Net Interest +
Other Inc/(Exp)

284M
Q4

Share
Count

Anti-dilutive
share repurchases
at a minimum⁽³⁾

(1) As of August 27, 2025, based on forecasted currency exchange rates. Presented on a non-GAAP basis.

(2) Core growth is reported growth adjusted for the effects of acquisitions and divestitures, and FX.

(3) The 2024 Stock Repurchase Program that authorized up to \$2 billion was approved by the Board in May 2024. The new program became effective on August 1, 2024 and will commence upon the termination of our 2023 Stock Repurchase Program.



Agilent
Trusted Answers



Get in touch
with us



investor_relations@agilent.com



www.investor.agilent.com